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Context: Increased abdominal fat has been linked to insulin resis-
tance and increased cardiovascular risk. Because many patients with
polycystic ovary syndrome (PCOS) present abdominal obesity, it may
be the cause of insulin resistance in this disorder.
Setting: Fat quantity and distribution were evaluated by dual x-ray
absorptiometry at the Departments of Clinical Medicine at the Uni-
versity of Palermo and the University of Naples, Italy.
Patients:A total of 110 patients with PCOS and 112weight-matched
controls were studied. Anthropometric data, blood glucose, serum
insulin, and testosterone were evaluated. Total, trunk, and central
abdominal fat quantity were measured by total-body dual x-ray
absorptiometry.
Results: Compared with weight-matched controls, patients with
PCOS had similar quantity of total and trunk fat but higher quantity
of central abdominal fat. This difference was not observed when com-
paring obese PCOS and obese controls but depended on differences
between overweight andnormoweight patients and controls. All obese
subjects, independently of having PCOS or not, had increased central
abdominal fat. The same parameter was increased in 71% of over-
weight PCOS, 50% of overweight controls, and 30% of normoweight
PCOS patients. PCOS patients with increased central abdominal fat
had significantly higher (P  0.01) insulin levels and significantly
reduced (P  0.01) insulin sensitivity than controls with similar
quantities of central abdominal fat. Overweight PCOS patients with
normal abdominal fat had significantly higher (P  0.05) insulin
levels and significantly reduced (P  0.05) insulin sensitivity than
overweight controls with normal abdominal fat.
Conclusions:Most obese subjects, independent of being affected by
PCOS, have an abdominal form of obesity. However, abdominal fat
excessmay not be the only determinant of insulin resistance in PCOS.
(J Clin Endocrinol Metab 92: 2500–2505, 2007)
OBESITY IS A CLASSIC characteristic of polycysticovary syndrome (PCOS) (1, 2). Although profound
differences, probably depending on environmental causes,
exist in the prevalence of obesity in different countries (3) and
also in areas, such as southern Italy, where obesity in PCOS
is less common than in the United States, 70% ofwomenwith
PCOShave increased bodyweight [bodymass index (BMI)
25 kg/m2] (4).
However, for many years, there has been relatively little
attention on the importance of fat excess in determining the
reduced insulin sensitivity that is found in most PCOS pa-
tients. In fact, it was shown that, in this disorder, insulin
resistance is more severe than that expected on the basis of
body weight (5–9). In addition, insulin resistance may be
found also in 30–50% of PCOS women having normal body
weight (5–9). Therefore, it was suggested that insulin resistance
and cardiovascular (CV) risk exist in PCOS independently of
obesity, although fat excess, when present, worsens insulin
resistance, which in turn further enhances CV risk (5, 6).
However, these concepts have been challenged by the
finding that, in the general population, fat excess in partic-
ular body regionsmay be linked to insulin resistance and CV
risk, independently of the total quantity of body fat (10–13).
Obese patients with peripheral distribution of fat have a
relatively low CV and metabolic risk, whereas patients with
prevalently abdominal obesity have higher insulin levels,
more severe lipid alteration, and increased production of
inflammatory substances. Most of these differences have
been attributed to the increase of visceral fat (14, 15), but sc
abdominal fat is also metabolically active (15–18) and some
data suggest that it may be as important as visceral fat, at
least regarding insulin resistance (17) and some early alter-
ations of endothelium (18).
Because most PCOS patients exhibit an abdominal form of
obesity (19–21), recently it has been suggested that increased
visceral fatmay be the cause or the early consequence of their
insulin resistance (22).
However, the available data onmeasurement of visceral or
total abdominal fat in women with PCOS do not support the
statement that these patients have a larger quantity of vis-
ceral or total abdominal fat than weight-matched controls
(23–26). In fact, contrasting results have been presented (23–
26) and, in addition, in all studies the number of controls was
quite low [from a minimum of 15 (25) to a maximum of 30
(23)].
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In this study, using total-body dual x-ray absorptiometry
(DXA), we assessed several fat quantity parameters in a large
number of women with PCOS and an equal number of con-
trols. Because small changes of body weight may determine
relatively largemodifications in fat mass, particular care was
given to weight matching of controls.
The objectives of the study were to determine whether
total and/or abdominal fat quantity is larger in PCOS than
weight-matched controls and to assess whether PCOS pa-
tients and controls with similar total or abdominal fat quan-
tity present similar circulating insulin levels and similar in-
sulin sensitivity.
Patients and Methods
Patients and control subjects
One hundred ten consecutivewomen of reproductive agewith PCOS,
all referred because of androgen excess to our Endocrine Units, were
included in the present study. The diagnosis of PCOS was based on the
presence of clinical or biological hyperandrogenism and chronic anovu-
lation and the exclusion of adrenal enzymatic deficiency (by measure-
ment of serum 17-hydroxyprogesterone), Cushing’s syndrome, or an-
drogen-secreting tumors (27).
Clinical hyperandrogenismwas defined as the presence of hirsutism,
acne, or androgenic alopecia. Hirsutism was assessed by Ferriman-
Gallwey-Lorenzo scores (28) (patients with scores  6 were considered
hirsute), whereas acne was graded by a scoring system from 0 to 3 (29),
and alopecia was evaluated by the Ludwig scoring system (30).
Biochemical hyperandrogenism was defined as serum testosterone
greater than 60 ng/dl (2.08 nmol/liter) and/or free testosterone 3
pg/ml or greater (10.34 pmol/liter) and/or serum dehydroepiandro-
sterone sulfate 3000 g/liter or greater (7.8 mol/liter). These values
of hyperandrogenismhave been previously calculated in our population
with the same assays (31).
Anovulation was defined as serum P less than 3 ng/ml (9.54 nmol/
liter). In patientswith normalmenses, at least two consecutivemenstrual
cycles were studied, and low levels of serumP (3 ng/ml) in both cycles
indicated the presence of chronic anovulation. Therefore, the studied
patients presented the classic, more severe form of PCOS (32).
The project design included amedical examination, biochemical anal-
yses, and DXA determination of fat quantity and distribution. The
adopted procedures were in agreement with the Helsinki Declaration of
1975 as revised in 1983, and the study was approved by the local ethics
council. All subjects gave their informed consent to participate in the
study. At admission all subjects underwent a medical examination and
also answered a questionnaire on personal andmedical items, including
age, past medical history, and use of medications. Exclusion criteria
included the presence of renal or hepatic diseases. No patient had type
2 diabetes, and no patient had taken medications for at least 3 months.
Height, weight, and waist circumference (measured at the midpoint
between the lateral iliac crest and the lowest rib margin at the end of
normal expiration) were recorded and BMI was calculated as kilograms
per square meter.
As controls, we selected a group of 112 healthy female subjects,
matched for age and body weight, with the same exclusion criteria
described above. They were recruited from family members of hospital
coworkers. Controls were women with regular menses, no clinical or
biological hyperandrogenism, and normal (7 ng/ml in d 22 of the
cycle) serum progesterone levels.
A main objective of the study design was to match patients and
controls by not only total mean body weight but also body weight
distribution to have a similar number of controls and PCOS women and
a similar mean body weight inside the subgroups of normoweight (BMI
20–24.9 kg/m2), overweight (BMI 25–29.9 kg/m2), and obese (BMI
30–40 kg/m2) subjects. Because in our PCOS population the three dif-
ferent weight subgroups are equally represented (4), we intended to
study about 40 patients and 40 controls for each weight subgroup.
Therefore, consecutively studied PCOS patients were included in three
different subgroups according to their BMI (normal, overweight, and
obese), and in each subgroup, every 20 PCOS patients and 20 body
weight-matched controls were selected and studied. The final number
was slightly lower than 40 patients for weight subgroup because some
patients did not complete the endocrine evaluation and were excluded
from the study.
No patient or control had a BMI higher than 40 kg/m2.
In all women with PCOS and normal controls, during the follicular
phase (d 5–8), a fasting blood sample was obtained between 0800 and
0900 h for measurements of insulin, glucose, and testosterone.
Assays
Plasma glucose levels were determined by the glucose oxidase tech-
nique. Insulin was determined with a double antibody method using
reagents obtained from Linco Research, Inc. (St. Charles, MO). Insulin
resistance was calculated by the quantitative insulin-sensitivity check
index (QUICKI) (9, 33, 34). Testosterone was determined by a RIA
method after extraction and chromatography (35).
In all hormonal assays, the intraassay coefficient of variation was less
than 6%, and the interassay coefficient of variation was less than 15%.
Fat determination
In both departments of Clinical Medicine, fat quantity was deter-
mined by total body DXA using a similar Instrument (QDR Discovery;
Hologic, Bedford, MA). Total fat quantity and quantity of fat in trunk
area were measured. Quantity of fat was determined also in central
abdominal area (R1 area), an area of 50 cm2 around the central point of
the midline between the lateral iliac crests and the lowest rib margins
at the end of normal expiration (the same midline used for waist cir-
cumference). The central point of R1 area generally but not always
corresponded to the umbilicus. To assess fat distribution, percent of total
fat in trunk and R1 area were also calculated.
Statistical analysis
Statistical analyses were performed using Statview 4.5 (Abacus Con-
cepts Inc., Berkeley, CA) and SPSS 9.0 for PC (SPSS Inc., Chicago, IL).
Univariate analyses were performed using Student’s unpaired t test for
the numeric variables, whereas the differences in the prevalences for the
nominal variables were analyzed by 2 test. Analysis of covariance was
used to assess the differences in fat quantity and distribution and bio-
chemical parameters between subgroups of patients and controls. Cor-
relation analyses were performed using the Spearman rank correlation
method. All data are expressed as mean  sd.
Results
Patients with PCOS and matched controls had similar age
(25.1  4.9 vs. 24.9  3 yr), whereas testosterone (80.7  29
vs. 41 9 ng/dl) and insulin (14.8 5 vs. 11.3 5.1 U/ml)
were significantly higher (P  0.01) in PCOS than controls.
QUICKIwas significantly lower (0.324 0.02 vs. 0.351 0.02,
P  0.01) in PCOS than matched controls.
As shown in Table 1, BMI, total fat, and trunk fat quantity
were similar in PCOS and weight-matched controls. How-
ever, waist circumference, R1 fat quantity, percent trunk fat,
TABLE 1. Fat parameters by total-body DXA in PCOS and
controls
PCOS
(n  110)
Controls
(n  112)
BMI 28.0  5.5 28.0  5.6
Waist circumference (cm) 92.4  15.1a 88.2  12.8
Total fat (g) 27,307  10,182 27,020  10,143
Trunk fat (g) 11,830  5,772 10,981  5,320
Trunk fat vs. total fat (%) 41.4  6.1a 38.9  6.3
R1 fat (g) 785  387a 679  363
R1 fat vs. total fat (%) 2.78  0.50a 2.46  0.49
a P  0.01.
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and percent R1 fat were significantly higher in PCOS than
weight-matched controls.
Fat parameters in patients and controls divided by body
weight
Thirty-five PCOS patients (31.8%) and 36 controls (32.1%)
were obese (BMI  30 kg/m2). As shown in Table 2, all fat
parameters were similar in obese PCOS and obese controls.
Thirty-five PCOS patients (31.8%) and 36 controls (32.1%)
were overweight (BMI  30 but  25 kg/m2). As shown in
Table 2, BMI, total fat, trunk fat, and percent trunk fat were
similar in overweight PCOS and controls, whereas waist
circumference, R1 fat, and percent R1 fat were higher in
overweight PCOS, compared with overweight controls.
Forty PCOS patients (36.4%) and 40 controls (35.8%) had
normal body weight (BMI between 19 and 24.9 kg/m2). As
shown in Table 2, BMI, total fat, and trunk fat were similar
in the two groups of subjects. However, waist circumference,
R1 fat, percent trunk fat, and percent R1 fatwere significantly
higher in normoweight PCOS, compared with normoweight
controls.
Correlations between anthropometric measures and fat
parameters
In total group (PCOS controls), body weight (expressed
as BMI) strongly correlated (P 0.01) with total fat (r 0.94),
trunk fat (r  0.93), and central abdominal fat (R1: r  0.89).
BMI also correlated with fat distribution but r values, al-
though statistically significant, were lower (with percent
trunk fat 0.69, P  0.01; with percent R1 fat 0.41, P  0.05).
Waist circumference exhibited similar correlations (with
total fat 0.90, trunk fat 0.91, R1 fat 0.91, percent trunk fat 0.69,
with percent R1 fat 0.47). When separately evaluating PCOS
and controls, similar correlations were found.
When evaluating only obese subjects, the same correla-
tions were observed. However, in overweight and normo-
weight subjects, no correlation betweenR1 fat and percent R1
fat with BMI or waist circumference was found.
Correlation between fat and biochemical parameters
When evaluating all patients and controls together, serum
insulin correlated with all fat parameters. The best correla-
tions were with percent R1 fat (r 0.58, P 0.01) and R1 fat
(r  0.41, P  0.01). QUICKI negatively correlated with all
fat parameters. The best correlations were with R1 fat (r 
0.56, P  0.01) and percent R1 fat (r  0.49, P  0.01).
When separately evaluating PCOS and controls, similar find-
ingswere observed, but the correlationsweremuch stronger.
In PCOS patients, the stronger correlations were between
serum insulin and R1 fat (r 0.65, P 0.01) and between R1
fat and QUICKI (r  0.73, P  0.001).
When dividing patients and controls by BMI, similar cor-
relations were found. In the group of PCOS patients, central
abdominal fat showed stronger correlations with insulin and
QUICKI in overweight (with insulin: r  0.81, P  0.01;
QUICKI: r0.76, P 0.01) and normoweight (with insulin
r  0.69, P  0.01; QUICKI: r  0.66, P  0.01) than obese
(with insulin: r 0.34, P 0.05; QUICKI: r0.49, P 0.01)
PCOS patients.
No correlations were found between serum testosterone
and fat parameters.
Assessment of normal and pathological values of fat
parameters
The mean  2 sd values of normoweight controls were
used to determine the upper normal ranges of fat parameters.
Therefore, the following values were considered higher than
normal values: total fat, 23,400 g; trunk fat, 8,800 g; R1 fat,
560 g.
Total fat was increased in all obese patients and controls
and normal in all normoweight patients and controls. Total
fat was increased in 20 overweight PCOS patients (57%) and
in 22 overweight controls (61%).
Trunk fat was increased in all obese subjects (both PCOS
patients and controls) but also in 71% of overweight PCOS
patients and 72% of overweight controls. All normoweight
controls had normal trunk fat, whereas five normoweight
PCOS patients (12.5%) had increased trunk fat.
Central abdominal fat was increased in all obese subjects
(both PCOS and controls) and also 71% of overweight PCOS
and 50% of overweight women. Central abdominal fat was
normal in all normoweight controls but was increased in 12
normoweight PCOS patients (30%).
Biochemical parameters in PCOS patients and controls
with increased central abdominal fat
Insulin, QUICKI, and testosterone levels were compared
in patients and subjects divided according to excess or not of
central abdominal fat. Because central abdominal fat was
increased in all obese subjects, the entire groups of obese
PCOS and controls were compared. In obese PCOS, serum
insulinwas significantly higher (P 0.01) (17.8 4.5U/ml)
TABLE 2. Fat parameters by total-body DXA in PCOS patients and controls, divided according to body weight
Obese PCOS
(n  35)
Overweight
PCOS
(n  35)
Normoweight
PCOS
(n  40)
Obese controls
(n  36)
Overweight
controls
(n  36)
Normoweight
controls
BMI (kg/m2) 34.4  3.8 27.8  1.1 22.4  1 34.5  3.8 27.8  1.8 22.4  1.5
Waist circumference (cm) 108  16 89.7  5.5a 79.9  4.8b 102  12.3 85.8  5.6 77.6  3.3
Total fat (g) 39,101  3,193 26,628  5,515 17,304  2,393 38,334  6,347 25,782  4,804 17,492  2,934
Trunk fat (g) 18,630  3,094 11,101  3,300 6,366  1,443 17,485  2,632 10,219  2,315 5,813  1,486
Trunk fat vs. total fat (%) 46.9  4.1 41.2  5.2 36.6  5.1a 44.9  4.3 39.7  4.1 32.8  3.3
R1 fat (g) 1,223  294 719  219a 451  103a 1,119  215 586  119 344  107
R1 fat vs. total fat (%) 3.14  0.57 2.64  0.35a 2.60  0.37a 2.89  0.49 2.27  0.28 2.22  0.37
a P  0.01 vs. controls of similar body weight.
b P  0.05 vs. controls of similar body weight.
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and QUICKI was significantly lower (0.309  0.01) than in
obese controls (insulin 13 3 U/ml; QUICKI 0.333 0.01).
As shown in Figs. 1 and 2, overweight PCOS patients with
increased central abdominal fat had significantly higher (P
0.01) values of serum insulin and significantly lower (P 
0.01) QUICKI than overweight PCOS patients with normal
central abdominal fat and overweight controls with in-
creased or normal central abdominal fat. PCOS patients with
normal central abdominal fat had similar values of insulin
and QUICKI than overweight controls with central abdom-
inal fat, and both subgroups had significantly higher (P 
0.05) insulin and lower QUICKI values than overweight con-
trols with normal central abdominal fat. No differences in
serum testosterone among the different subgroups of over-
weight PCOS patients were observed.
Serum insulin and insulin resistance calculated by QUICKI
were significantly higher (P  0.01) in normoweight PCOS
patients with increased central abdominal fat than normo-
weight PCOS patients with normal central abdominal fat and
normoweight controls (Figs. 3 and 4). No differences in insulin
levels and insulin resistance between these two subgroups of
subjects were observed. No differences in serum testosterone
betweennormoweight PCOSwith normal or increased abdom-
inal fat were found.
Discussion
Although women with PCOS present anthropometric ev-
idence of abdominal obesity (19–21), in these patients pre-
vious measurements of abdominal fat quantity have given
contrasting results (24–26). In fact, whereas some studies
showed increased abdominal fat (23, 24) or increased trunk
to extremity fat ratio (25), in other studies no differences in
total or trunk fat quantity between patients and weight-
matched controls were found (26).
The different results probably depend on the small num-
ber of studied patients and controls but may also depend on
the method used. In fact, one small study assessed visceral
fat by ultrasonography (23), whereas in other studies total
trunk fat was measured by DXA (24–26).
Different methods may be used to assess fat quantity and
distribution, each presenting advantages and disadvantages.
In a small group of subjects, multislice computed tomogra-
phy or magnetic resonance imaging scanning is the best
method because it allows one to distinguish andmeasure the
different compartments of sc fat and the visceral abdominal
fat (14, 17). However, these methods may be used only in a
small group of particularly selected patients but not in
screening studies of large populations. Ultrasound evalua-
tion of sc and visceral abdominal fat has also been used (14,
35), but this method, although simple and feasible in large
populations, is largely operator dependent and has reduced
sensitivity in normoweight or slightly overweight patients
(35).
In this studyweused total-bodyDXA to assess fat quantity
and distribution (36). The main advantage of the DXA
method is the possibility to measure directly the quantity of
fat in different body regions, giving numerical data that are
independent of the operator. It is a simple method that may
be used in large populations. The main disadvantage is the
impossibility to differentiate sc from visceral abdominal fat.
However, because sc abdominal fat is also metabolically
active and linked to insulin resistance (17) and vascular early
alterations (18), assessment of abdominal fat by DXA is a
good indicator of metabolic and cardiovascular conse-
quences of obesity (17, 36) andmay be a better indicator than
simple visceral fat determination (16).
DXA software assesses body composition in the trunk, an
area that includes not only the abdomen but also the thorax.
FIG. 3. Serum insulin in normoweight PCOS patients and controls.
To convert to picomoles per liter, multiply by 7.18. *, P  0.05 vs.
normoweight controls.
FIG. 1. Serum insulin in overweight PCOS patients and controls. To
convert to picomoles per liter, multiply by 7.18. *, P  0.05 vs. over-
weight controls with normal abdominal fat; **, P  0.01 vs. over-
weight controls with normal abdominal fat.
FIG. 2. Insulin sensitivity (calculated by QUICKI) in PCOS patients
and controls. *, P  0.05 vs. overweight controls with normal abdom-
inal fat; **, P  0.01 vs. overweight controls with normal abdominal
fat.
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Because of this, to improve the sensitivity of the method,
some authors measured the fat quantity in the area between
the first and fourth lumbar vertebra (36). We preferred to
assess fat quantity in the central abdominal region, evalu-
ating an area of 50 cm2 around the midpoint of the midline
between the lateral iliac crests and the lowest rib margins at
the end of normal expiration. This method presents the ad-
vantage of measuring abdominal fat in the same area that is
used for assessing waist circumference and abdominal sag-
ittal diameter. In fact, it has been shown that these two
parameters are better correlates of abdominal visceral adi-
pose tissue accumulation and cardiovascular disease risk
factors than othermeasures of bodyweight or fat distribution
(37).
By evaluating a large population of PCOS patients and
carefully weight-matched controls (a total of 222 subjects),
we found that, despite the difference in the simple measure-
ment of waist circumference, PCOS patients and controls
have similar quantities of not only total fat but also trunk fat.
Only percent trunk fat was significantly increased in PCOS
patients, confirming the data reported by Puder et al. (25).
However, central abdominal fat was significantly increased
in PCOS patients, indicating that, by improving the sensi-
tivity of the method, it is possible to demonstrate that PCOS
patients have increased fat in abdominal region.
By dividing the patients in subgroups according to body
weight, we observed that this difference ismainly dependent
on differences in abdominal fat accumulation in overweight
and normoweight PCOS patients, compared with controls of
similar body weight. In fact, when comparing obese PCOS
and obese controls, all fat parameters were similar. Probably
when obesity is present, most subjects, independently of
having PCOS or not, have an abdominal obesity. One hun-
dred percent of our obese controls (and 100% of our obese
PCOS patients) showed increased quantity of trunk and cen-
tral abdominal fat. On the other hand, it has been reported
that at least 80% of obese subjects are affected by abdominal
obesity (11, 12).
On the contrary, when compared with controls with sim-
ilar body weight, overweight and normoweight PCOS pa-
tients had an increased quantity of central abdominal fat.
Interestingly, in these patients, anthropometric measures
(BMI or waist circumference) did not permit us to predict the
presence of central abdominal fat excess, and this suggests
that DXA evaluation of fat quantity and distribution may be
particularly useful in such PCOS patients.
Because abdominal fat is strongly correlated with insulin
and insulin resistance (as confirmed by our own data), the
presence of increased abdominal fat in a large proportion of
nonobese PCOS may indicate that the finding of hyperin-
sulinemia and insulin resistance in PCOS, compared with
weight-matched controls, is just the consequence of abdom-
inal obesity in a larger proportion of subjects. However, our
study suggests that the increase in abdominal fat is not the
only determinant of hyperinsulinemia and insulin resistance
in PCOS. Comparing patients and controls with similarly
increased quantities of central abdominal fat, we found that
PCOS patients had higher insulin levels and reduced insulin
sensitivity.
In fact, obese PCOS patients, despite presenting similar
abdominal quantity of fat than obese controls, had higher
insulin and more severe insulin resistance than obese con-
trols. In addition, overweight PCOS patients with increased
abdominal fat had higher insulin and lower QUICKI than
overweight controls with similarly increased abdominal fat.
Finally, overweight PCOS patients with normal central ab-
dominal fat had higher insulin levels and lower insulin sen-
sitivity than overweight controls with a similar quantity of
abdominal adipose tissue.
These data suggest that factors different from abdominal
fat may be involved in the increase of insulin levels and
insulin resistance of PCOS patients.
A similar evaluation between normoweight PCOS and
controls was not possible because all normoweight controls
exhibited normal abdominal fat. However, normoweight
PCOS with normal central abdominal fat did not show any
evidence of hyperinsulinemia and insulin resistance. These
patients are relatively common in our population and, in this
study, 28 PCOS patients (25% of studied PCOS women) had
normal body weight and normal central abdominal fat.
It is difficult to reconcile the differences in results between
obese and overweight PCOS who present higher insulin and
reduced insulin sensitivity than controls with similar ab-
dominal fat and normoweight PCOSwith normal abdominal
fat who have similar insulin and insulin sensitivity, com-
pared with their own controls.
Maybe normoweight controls with normal fat quantity
and distribution represent a subgroup of PCOS in whom
insulin resistance does not have a role in the pathogenesis of
the disorder. In fact, insulin resistance may influence fat
distribution, and it is probable that the differences in fat
distribution that we observed in PCOS patients are the con-
sequence of reduced insulin sensitivity.
In this studywe did notmeasure visceral fat but measured
only sc and visceral central abdominal adipose tissue. Mul-
tislice computed tomography scanning determination of dif-
ferent compartments of abdominal fat, followed by compar-
ison of populations of PCOS women and control women
with similar quantities of visceral fat,may be needed to better
understand the relationships between fat distribution and
insulin sensitivity in PCOS. However, it is unlikely that pa-
tients and controls with similar quantities of total, trunk, and
central abdominal fat have substantial differences in quantity
of visceral fat. In fact, patients with a higher quantity of
FIG. 4. Insulin sensitivity in normoweight PCOS patients and con-
trols. **, P  0.01 vs.normoweight controls.
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visceral fat should have a lower quantity of abdominal sc fat.
On the other hand, it has been shown that the profound
component of sc abdominal fat is probably more important
than visceral fat in determining insulin resistance (17),
whereas visceral fat seems to be more related to increased
inflammatory activity of adipose tissue.
In conclusion, we have shown that not only obese PCOS
patients but also a large proportion of overweight PCOS
patients and a minority of normoweight PCOS patients have
increased abdominal fat. Although this alteration may con-
tribute to hyperinsulinemia and reduced insulin sensitivity,
it is unlikely to be the only determinant of insulin resistance
of PCOS. In fact, when comparing obese and overweight
patients and controls with similar quantities of abdominal
fat, PCOS patients still have higher insulin levels and re-
duced insulin sensitivity. As a partial exception, normo-
weight PCOS patients with normal abdominal fat presented
similar insulin levels and insulin sensitivity than normo-
weight controls. Further studies are needed to understand
better the relationships between fat distribution and insulin
sensitivity in PCOS.
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